Exhibit 10.17

 

CONFIDENTIAL TREATMENT REQUESTED.  CONFIDENTIAL PORTIONS OF THIS DOCUMENT HAVE
BEEN REDACTED AND HAVE BEEN SEPARATELY FILED WITH THE COMMISSION.

 

 

[g300353kg05i001.jpg]

 

October 18, 2011.

 

 

Ms. Kathy Hibbs

Senior Vice President & General Counsel

Genomic Health, Inc.

301 Penobscot Drive

Redwood City, CA 94063

 

Re:

Agreement effective February 5, 2005 between Roche Molecular Systems, Inc.
(“RMS”)

 

and Genomic Health, Inc. (“GH”) for use of the Polymerase Chain Reaction (PCR)

 

technology in human in vitro diagnostic services (“the Agreement”)

 

Dear Ms. Hibbs:

 

Pursuant to the terms of the Agreement and our recent communications regarding
Combination Services, enclosed is a revised Attachment II effective July 1,
2011, which reflects the change in the royalty bearing fraction of GH’s Oncotype
assays from ***% to ***% and which supersedes the previous Attachment II.

 

Please acknowledge GH’s acceptance of the new Attachment II by having an
authorized representative of GH execute both copies of this letter, each of
which, once executed, shall constitute an original.  Please forward one of the
executed duplicate originals to the attention of Donna Donohue, Licensing
Manager, at the below address, retain the other, and replace the dated
Attachment II in your Agreement with this version.

 

Sincerely,

 

Agreed and Accepted

ROCHE MOLECULAR SYSTEMS, INC.

 

GENOMIC HEALTH, INC.

 

 

 

 

 

 

 

/s/ Sushma Selvarajan

 

By:

/s/ Kimberly J. Popovits

Sushma Selvarajan

 

 

(authorized signature)

Head of Business Development

 

 

 

 

 

Name:

Kimberly J. Popovits

 

 

 

 

 

 

Title:

President & CEO

dd

 

 

 

Enclosure

 

Date:

10.21.11

 

 

 

 

 

 

 

 

Apprv’d As To Form

 

 

LAW DEPT.

 

 

By:

/s/ [ILLEGIBLE]

 

 

 

 

 

 

 

 

 

Roche Molecular Systems, Inc.

 

4300 Hacienda Drive   

 

 

PO Box 9002

 

 

Pleasanton, CA 94566-0900

 

 

USA

 

--------------------------------------------------------------------------------

*** CONFIDENTIAL MATERIAL REDACTED AND SEPARATELY FILED WITH THE COMMISSION.

 

--------------------------------------------------------------------------------

 

ATTACHMENT II

 

COMBINATION SERVICES

 

 

 

Percent of Net Service

 

 

 

Revenues for Combination

 

 

 

Services which is Attributable

 

Licensed Service(s)

 

to Licensed Service(s)

 

 

 

 

 

Oncotype DX

 

***

%

 

 

This revision is effective as of July 1, 2011

 

--------------------------------------------------------------------------------

*** CONFIDENTIAL MATERIAL REDACTED AND SEPARATELY FILED WITH THE COMMISSION.

 

--------------------------------------------------------------------------------